1083 Background: Resistance to endocrine therapy (ET) in breast cancer (BC) patients is frequently associated with acquired ESR1 gene mutations like the Y537S, which triggers a constitutive estrogen receptor (ERα) activation. Therefore, the identification of novel therapeutic strategies is crucial for the management of ER-positive, ET-resistant BC. In this context, PARP1 poly(ADP-ribose) polymerase 1 (PARP-1) has emerged as a promising therapeutic target, based on its involvement in the regulation of oxidative DNA damage in BC cells. Methods: Data from the METABRIC dataset were used to assess the clinical relevance of PARP-1 in ER-positive BC patients. As experimental models, MCF7 and T47D BC cell lines expressing ERα wild type (wt) or Y537S mutation were used. PARP-1 regulation was investigated by western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) assays. Gene expression, promoter assays, and chromatin immunoprecipitation sequencing (ChIP-seq) studies allowed us to analyze the transcriptional activity mediated by ERα. Cell cycle, proliferation and colony formation experiments as well as in vivo studies were performed to evaluate the biological effects of the PARP-1 inhibitor niraparib. Results: We observed that the up-regulation of PARP-1 upon exposure to 17β-estradiol (E 2 ) occurs through ERα in BC cells expressing either ERα wt or Y537S mutation. Moreover, we assessed that the transcriptional activity of ERα relies on PARP-1, as demonstrated by the ability of nirabarib to prevent the transactivation of ERα and the regulation of ERα target genes. In addition, niraparib halted the proliferation and cycle progression of BC cells expressing either ERα wt or Y537S mutation. Of note, niraparib suppressed primary tumor growth in xenograft tumors derived from ERα Y537S mutated MCF7 cells. Conclusions: Our data suggest that crosstalk between PARP-1 and ERα is involved in the proliferative responses of ERα wt or Y537S mutated BC cells. Therefore, targeting PARP-1 could provide a promising strategy to overcome the ET resistance of BC cells.
Read full abstract